RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 16:54:34(美东 04:54)·⟳ 抓取 16:55:06 +32s·⚡ 决策 10-26 16:57:43 +2m37s·1.2 天前
Genmab公布petosemtamab联合化疗治疗转移性结直肠癌II期随访更新（ESMO 2026），系重复消息无新增事实
本条RTTNews报道与本臂10月25日12:50 UTC已处理的Genmab公司通稿（GlobeNewswire/IR）及13:28 UTC已处理的Investing.com改写文为同一ESMO 2026 II期随访催化，ORR 75%/67%、DCR 95%/93%、安全性、III期LiGeR等关键事实完全一致，无任何新增数据（无PFS/OS、无III期结果、无注册进展）；事件本身为单臂II期渐进式随访更新，且GMAB在消息前的10月23日已单日上涨9.48%、盘前再涨2.49%，增量已被市场消化。
📄 原文RTTNews Biotech↗ 原文
Genmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal Cancer
Genmab (GMAB) reported updated Phase 2 data showing that Petosemtamab, when combined with standard chemotherapy, contin…
不做 Genmab A/S（GMAB.US）
重复消息：RTTNews改写文与10-25已处理的公司通稿为同一ESMO 2026 II期随访催化，无任何新增事实；数据为单臂II期更新（非III期/非注册），且GMAB 10月23日已涨9.48%、盘前续涨2.49%，催化已被定价，短线无正期望edge。下一实质催化为III期LiGeR读出与10月28日投资者会。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews这条只是Genmab ESMO II期随访数据的第三次媒体改写，公司通稿已于10月24-25日发布并被本臂两次判定不做，无新增事实，且II期单臂更新对大盘biotech增量有限、股价已提前反应，不做。
消息传播链
- 节点
- 节点
关键理由
- 事件方向虽为正面（ORR/DCR数据巩固、安全性可控），但属单臂II期随访更新，非III期阳性或注册催化，不改变petosemtamab的状态迁移
主要风险
- 下一实质催化为III期LiGeR读出及10月28日投资者更新会，届时才可能产生新的预期差；本条旧闻重提不构成交易edge
先例如何影响了这次决策
对本次决策的影响:查重确认重复后直接AVOID，先例不改变结论
方向:未做外部先例统计：本条在跨源查重阶段即确认为同一催化的重复媒体改写且无新增事实，按早停规则不再进入先例研究
涨幅量级:不适用（重复消息早停）
形态:不适用
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 181 ms
{"result": "search_processed_events:agent query=`genmab petosemtamab phase 2 metastatic colorectal cancer esmo 2026 | gmab petosemtamab updated data folfox folfiri ras braf wild-type | petosemtamab egfr lgr5 bispecific mcrc respo`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 66.7/72 小时、2031 条本臂决策(完整)，返回 2 条候选。\n• 10-25 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 2,121 ms
豆包搜索结果（原始查询:Genmab petosemtamab Phase 2 colorectal cancer ESMO 2026 data；API SearchType:web）
原文全文
展开原文 · 2,822 字
Genmab (GMAB) reported updated Phase 2 data showing that Petosemtamab, when combined with standard chemotherapy, continued to demonstrate encouraging response rates in patients with metastatic colorectal cancer (mCRC). The findings were presented at the ESMO Congress 2026 and support the company's ongoing global Phase 3 program.
Metastatic colorectal cancer occurs when cancer of the colon or rectum spreads to other parts of the body. While treatment options have improved, many patients continue to face poor outcomes after the disease advances.
The Phase 2 study evaluated Petosemtamab, an investigational bispecific antibody targeting EGFR and LGR5, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
At median follow-up of 5.9 months in the first-line patients and 7.1 months in second-line pateitns, the therapy demonstrated confirmed and unconfirmed objective response rates of 75% in first-line patients and 67% in second-line patients. Among first-line patients with left-sided tumors, the response rate reached 81%.
The updated analysis showed that several previously unconfirmed responses were later confirmed with longer follow-up, further supporting the durability and consistency of the treatment's anti-tumor activity.
Disease control rates remained high, reaching 95% in first-line patients and 93% in second-line patients. Responses were also observed in patients with liver metastases, a group that is often associated with poorer outcomes.
The safety profile remained generally manageable. Petosemtamab-related adverse events led to treatment discontinuation in a small number of patients, and no treatment-emergent adverse events resulting in death were reported.
The updated findings provide additional support for Genmab's ongoing Phase 3 LiGeR-CRC1 and LiGeR-CRC2 trials, which are evaluating Petosemtamab in first- and second-line metastatic colorectal cancer and are currently enrolling patients.
Beyond colorectal cancer, Petosemtamab is also being studied in multiple Phase 3 trials in recurrent or metastatic head and neck cancer as Genmab continues to expand the development of the investigational therapy.
GMAB has traded between $23.62 and $44.34 over the past year. The stock closed Friday's trading (October 23, 2026) at $43.79, up 9.48%. In pre-market trading the stock is at $44.88, up 2.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Metastatic colorectal cancer occurs when cancer of the colon or rectum spreads to other parts of the body. While treatment options have improved, many patients continue to face poor outcomes after the disease advances.
The Phase 2 study evaluated Petosemtamab, an investigational bispecific antibody targeting EGFR and LGR5, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
At median follow-up of 5.9 months in the first-line patients and 7.1 months in second-line pateitns, the therapy demonstrated confirmed and unconfirmed objective response rates of 75% in first-line patients and 67% in second-line patients. Among first-line patients with left-sided tumors, the response rate reached 81%.
The updated analysis showed that several previously unconfirmed responses were later confirmed with longer follow-up, further supporting the durability and consistency of the treatment's anti-tumor activity.
Disease control rates remained high, reaching 95% in first-line patients and 93% in second-line patients. Responses were also observed in patients with liver metastases, a group that is often associated with poorer outcomes.
The safety profile remained generally manageable. Petosemtamab-related adverse events led to treatment discontinuation in a small number of patients, and no treatment-emergent adverse events resulting in death were reported.
The updated findings provide additional support for Genmab's ongoing Phase 3 LiGeR-CRC1 and LiGeR-CRC2 trials, which are evaluating Petosemtamab in first- and second-line metastatic colorectal cancer and are currently enrolling patients.
Beyond colorectal cancer, Petosemtamab is also being studied in multiple Phase 3 trials in recurrent or metastatic head and neck cancer as Genmab continues to expand the development of the investigational therapy.
GMAB has traded between $23.62 and $44.34 over the past year. The stock closed Friday's trading (October 23, 2026) at $43.79, up 9.48%. In pre-market trading the stock is at $44.88, up 2.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ae1d818aea· 2026-10-26 16:57 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前